User profiles for J. Michot
Jean-Marie MichotGustave Roussy Verified email at gustaveroussy.fr Cited by 13990 |
[HTML][HTML] Immune-related adverse events with immune checkpoint blockade: a comprehensive review
JM Michot, C Bigenwald, S Champiat, M Collins… - European journal of …, 2016 - Elsevier
Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in
which therapeutic agents are used to target immune cells rather than cancer cells. The first …
which therapeutic agents are used to target immune cells rather than cancer cells. The first …
[HTML][HTML] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1
have recently obtained approval for the treatment of metastatic melanoma and advanced/…
have recently obtained approval for the treatment of metastatic melanoma and advanced/…
[HTML][HTML] Quinolones in 2005: an update
F Van Bambeke, JM Michot, J Van Eldere… - Clinical Microbiology …, 2005 - Elsevier
Quinolones are one of the largest classes of antimicrobial agents used worldwide. This
review considers the quinolones that are available currently and used widely in Europe (…
review considers the quinolones that are available currently and used widely in Europe (…
[HTML][HTML] Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure
…, JM Michot, PL Zinzani, J Kuruvilla… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
1. Cooksley CD, Avritscher EBC, Bekele BN, et al. Epidemiology and outcomes of serious
influenza-related infections in the cancer population. Cancer. 2005; 104: 618e628. 2. …
influenza-related infections in the cancer population. Cancer. 2005; 104: 618e628. 2. …
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Background Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the
switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the …
switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the …
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
…, D Moro-Sibilot, JM Michot, J Raimbourg… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Background & Aims Immunotherapy for metastatic cancer can be complicated by the onset
of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs …
of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs …
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
…, CH Moskowitz, JM Michot, J Kuruvilla… - Blood, The Journal …, 2017 - ashpublications.org
… J.-MM has received consulting fees from Bristol-Myers Squibb. JK has received research
funding from Roche; consultancy fees from Bristol-Myers Squibb, Gilead, Janssen, Roche, and …
funding from Roche; consultancy fees from Bristol-Myers Squibb, Gilead, Janssen, Roche, and …
Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer
A Simonaggio, JM Michot, AL Voisin, J Le Pavec… - JAMA …, 2019 - jamanetwork.com
Importance Although immune checkpoint inhibitors (ICIs), such as anti–PD-1 (programmed
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …